Clinical Report: Complement System Activation in Individuals Experiencing PASC

Overview

This study investigates complement activation markers in individuals with post-acute sequelae of SARS-CoV-2 (PASC). Findings indicate no significant differences in complement activation between PASC patients and controls, suggesting a lack of compelling evidence for complement system involvement in PASC.

Background

Post-acute sequelae of SARS-CoV-2 (PASC), commonly known as long COVID, affects a significant portion of individuals post-infection, leading to persistent symptoms that can last for months or years. Understanding the underlying mechanisms, including potential immune dysregulation, is crucial for developing effective management strategies. This study specifically examines the role of the complement system in PASC, a pathway previously implicated in various immune responses.

Data Highlights

No significant differences in complement activation markers (C3bc, C3bBbP, TCC) were found between PASC patients and control participants.

Key Findings

• No noteworthy differences in complement activation markers were identified between mild and severe PASC patients compared to controls.
• PASC is characterized by a range of symptoms persisting for at least two months post-infection.
• The majority of PASC patients had experienced a mild acute SARS-CoV-2 infection.
• Complement activation markers assessed included C3bc, C3bBbP, and TCC.
• Previous studies have suggested immune dysregulation as a potential mechanism in PASC.

Clinical Implications

Clinicians should be aware that current evidence does not support the routine use of complement activation assays in the evaluation of PASC. Management should remain symptom-focused, as no definitive biomarkers have been established for this condition.

Conclusion

The study concludes that there is insufficient evidence to support the role of complement system activation in PASC, highlighting the need for further research in this area.

Related Resources & Content

1. Infection — Sequelae Affecting Multiple Organs After Non-COVID-19 Respiratory Infections: A Comprehensive Review
2. Acta Neuropathologica — Characteristic patterns of complement deposition in NMOSD, MOGAD, and MS
3. Basic Research in Cardiology (Springer) — Activation of the C3a–C3aReceptor-axis is associated with endothelial dysfunction and glycocalyx damage in ST-elevation myocardial infarction
4. Long COVID Clinical Guidance | Long COVID | CDC
5. Complement System Dysregulation in the Immunopathogenesis of Long COVID: Systematic Evidence Synthesis
6. The Journal of Infectious Diseases — Cytokine Profiles Distinguish Acute and Recovery Phases of Cardiac Involvement Following COVID-19: A Multicohort Biomarker Analysis
7. Long COVID Clinical Guidance | Long COVID | CDC
8. Complement System Dysregulation in the Immunopathogenesis of Long COVID: Systematic Evidence Synthesis
9. Frontiers | Does C1 esterase inhibitor play a role in post COVID-19 neurological symptoms? A randomized, double-blind, placebo-controlled, crossover, proof-of-concept study
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.